Study wrapper · #533
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
Editor's note
This analysis draws on two multicenter phase III randomized trials (806 participants) to ask whether tesamorelin-driven visceral-fat reduction improves liver enzymes in people with HIV and abdominal obesity. Among participants with elevated baseline ALT or AST, researchers reported that visceral-fat responders experienced significantly greater reductions in ALT and AST than non-responders over 26 weeks, and that the improvement persisted at 52 weeks even after switching to placebo despite partial fat re-accumulation. The large phase III base strengthens this, though it is a responder-stratified secondary analysis using liver enzymes as surrogates rather than histology. It supports a coherent story: tesamorelin's visceral-fat reduction is associated with improved liver-enzyme markers, consistent with its later-demonstrated effects on liver fat.
Plain-language abstract
Researchers used data from two large trials (806 people) to see whether reducing deep belly fat with tesamorelin also improved liver blood tests (ALT and AST, which rise when the liver is stressed) in people with HIV and abdominal obesity. Among those who started with elevated liver enzymes, people whose deep belly fat responded to tesamorelin had bigger drops in ALT and AST over 26 weeks than those whose fat did not respond. Notably, this liver-enzyme improvement lasted through 52 weeks even in people who were switched to placebo and regained some belly fat. At the start, more deep belly fat went along with higher ALT. The authors conclude that meaningfully reducing deep belly fat with tesamorelin is associated with better liver blood tests. The study used blood markers rather than direct liver tissue examination.